In the past week, DBVT stock has gone up by 3.46%, with a monthly decline of -0.01% and a quarterly plunge of -27.01%. The volatility ratio for the week is 6.26%, and the volatility levels for the last 30 days are 7.30% for DBV Technologies ADR The simple moving average for the last 20 days is 0.48% for DBVT’s stock, with a simple moving average of -41.45% for the last 200 days.
Is It Worth Investing in DBV Technologies ADR (NASDAQ: DBVT) Right Now?
Moreover, the 36-month beta value for DBVT is 0.68. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for DBVT is 94.41M and currently, short sellers hold a 0.34% of that float. On October 23, 2024, DBVT’s average trading volume was 50.35K shares.
DBVT) stock’s latest price update
DBV Technologies ADR (NASDAQ: DBVT) has experienced a decline in its stock price by -0.14 compared to its previous closing price of 0.70. However, the company has seen a gain of 3.46% in its stock price over the last five trading days. globenewswire.com reported 2024-10-22 that Châtillon, France, October 22, 2024 DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025 VITESSE Phase 3 study evaluating the Viaskin Peanut patch in children ages 4 – 7 years-old exceeded enrollment goals; Topline results on track for 4Q 2025 European Medicines Agency (EMA) scientific advice confirms registration path for a Marketing Authorization Application (MAA) with the modified Viaskin peanut patch for a 1 – 7 year-old indication in Europe Company to host investor conference call at 5:00pm ET today DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DBV has agreed to guidance provided by the U.S. Food and Drug Administration (FDA) on a pathway under the Accelerated Approval Program for the Viaskin Peanut patch in toddlers ages 1 – 3 years-old and has also received scientific advice from the EMA on a 1 – 7 year-old indication in Europe.
Analysts’ Opinion of DBVT
Goldman gave a rating of “Neutral” to DBVT, setting the target price at $1.50 in the report published on May 10th of the previous year.
DBVT Trading at -10.14% from the 50-Day Moving Average
After a stumble in the market that brought DBVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.30% of loss for the given period.
Volatility was left at 7.30%, however, over the last 30 days, the volatility rate increased by 6.26%, as shares sank -4.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.45% lower at present.
During the last 5 trading sessions, DBVT rose by +3.46%, which changed the moving average for the period of 200-days by -59.59% in comparison to the 20-day moving average, which settled at $0.6966. In addition, DBV Technologies ADR saw -63.27% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DBVT starting from Mohideen Pharis, who sale 1,785 shares at the price of $0.98 back on Jul 29 ’24. After this action, Mohideen Pharis now owns 79,367 shares of DBV Technologies ADR, valued at $1,749 using the latest closing price.
Mohideen Pharis, the Chief Medical Officer of DBV Technologies ADR, sale 660 shares at $1.36 during a trade that took place back on May 24 ’24, which means that Mohideen Pharis is holding 81,152 shares at $898 based on the most recent closing price.
Stock Fundamentals for DBVT
Current profitability levels for the company are sitting at:
- -3.76 for the present operating margin
- 1.32 for the gross margin
The net margin for DBV Technologies ADR stands at -6.38. The total capital return value is set at -0.6. Equity return is now at value -72.64, with -53.29 for asset returns.
Based on DBV Technologies ADR (DBVT), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -7.85. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is 2.29.
Currently, EBITDA for the company is -96.66 million with net debt to EBITDA at 0.65. When we switch over and look at the enterprise to sales, we see a ratio of 1.03. The receivables turnover for the company is 0.67for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.29.
Conclusion
To wrap up, the performance of DBV Technologies ADR (DBVT) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
